Aspira Pathlab & Diagnostics Limited reported a net profit of ₹5.13 lakh for the financial year ended March 31, 2026, marking a significant decline from the previous year's performance.

The disclosure was made during the 53rd Annual General Meeting (AGM) held on September 25, 2026, via Video Conferencing (VC) and Other Audio Visual Means (OAVM). Chairman Dr. Haseeb Ahmad Drabu informed shareholders that the current year's profit stood in stark contrast to the net profit of ₹207.26 lakh recorded in the preceding fiscal year.

Meeting proceedings and attendance

The AGM commenced at 2:10 pm and concluded at 2:30 pm. The meeting was chaired by Dr. Haseeb Ahmad Drabu, with Managing Director Nikunj Velji Mange and Director Vaibhav Odhekar in attendance. Mrs. Kiran Raghavendra Awasthi, Chairperson of the Audit and Nomination & Remuneration Committees, was also present.

Attendance details for the virtual meeting are as follows:

Mr. Manoj Jain, Partner of M/s. Sarda Soni Associates LLP, attended as the representative of the Statutory Auditors. Ms. Prajakta V. Padhye, Partner of M/s. Nilesh A. Pradhan & Co., LLP, served as the Scrutinizer and Secretarial Auditor.

Key resolutions passed

Shareholders voted on several ordinary and special business items using remote e-voting facilities provided by NSDL. The voting window opened on September 22, 2026, and closed on September 24, 2026.

The following resolutions were transacted:

1. Adoption of audited standalone financial statements for FY26.
2. Re-appointment of Nikunj V Mange as Director retiring by rotation.
3. Approval of material related party transaction with M/s. Yashraj Research Foundation.
4. Re-designation of Nikunj Velji Mange as Managing Director.
5. Regularization of Vaibhav Odhekar’s appointment as Executive Director.

What the numbers show

The financial data presented at the AGM highlights a dramatic contraction in profitability. Net profit fell to ₹5.13 lakh in FY26 from ₹207.26 lakh in FY25. This represents a decline of over 97%, indicating severe pressure on the bottom line despite the continuation of operations. The magnitude of this drop suggests either a significant increase in operational costs, a sharp reduction in revenue, or one-time exceptional charges that impacted the FY26 results, although specific drivers were not detailed in the meeting minutes.

Jay Arvind Bhanushali, a promoter of Aspira Pathlab & Diagnostics Ltd , acquired 1,387 equity shares through open market transactions between September 11 and September 16, 2026.

The acquisition increased his total shareholding to 7,47,838 shares, representing 7.27% of the company’s voting capital. This marks a marginal rise from his previous holding of 7,46,451 shares, or 7.25%.

Disclosure Details

Bhanushali filed the disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, with the Bombay Stock Exchange on September 16, 2026. The filing confirms that none of the shares held by him are encumbered or pledged.

The company’s total equity share capital remains unchanged at ₹10,29,30,000, divided into 1,02,93,000 equity shares of ₹10 each.